Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NH102 in the Treatment of Depression
NCT06842992Phase 2Completed
- Sponsor
- Jiangsu Nhwa Pharmaceutical
- Start
- Dec 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of NH-102 in major depressive disorder (MDD) (5 arms), sponsored by Jiangsu Nhwa Pharmaceutical. Primary endpoint: 17-item Hamilton Depression Rating Scale at 6 weeks. Started Dec 2024; status: completed.
02
Drugs
NH-102
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06842992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06842992.